Receive regular headline summaries whenever high-quality news is generated for this page. We'll never share your email address with others.
|7/26/2022||Humacyte Preclinical Data on Small-Diameter Human Acellular
... applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release. Humacyte Investor Contact: Joyce Allaire LifeSci Advisors LLC +1-617-435-6602 [email protected] [email protected] Humacyte Media Contact: [email protected] ...
|7/25/2022||PolyPid Announces Presentation of Phase 2 D-PLEX‚ÇÅ‚ÇÄ‚ÇÄ Clinical Data at the Midwest Surgical Association 2022 Annual Meeting
... additional Company information, please visit https://www.globenewswire.com/Tracker?data=HPgJfqV2dXf6E_LCyI0wsBILsMoxhIPpxk8uIXFjUTuWIrCgkmnUTR9KcOH-YwNUtQDb5-0-VzLLdWiiRvfHGLou-YcUREGU0rd7YCwwsws= and follow us on [Twitter] and [LinkedIn] . Contacts: PolyPid Ltd. Ori Warshavsky COO ‚Äì US 908-858-5995 Investors: Bob Yedid LifeSci Advisors 646-597-6989 [email protected] Media Contact: Nechama Feuerstein 551-444-0784 [email protected] ...
|7/25/2022||Motus GI Announces 1-FOR-20 Reverse Stock Split
... only as of the date hereof. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Investor Contact: Troy Williams LifeSci Advisors (518) 221-0106 [email protected] ...
|7/25/2022||Aligos Therapeutics Initiates 12-Week Dosing Cohort in Phase 1b Study Evaluating Its Class II Capsid Assembly Modulator, ALG-000184||Globe Newswire|
|7/25/2022||Paratek Pharmaceuticals to Report Second Quarter 2022 Financial Results on August 3, 2022||Globe Newswire|
|7/22/2022||Pixium Vision announces its financial results for H1 2022 and provides a business update||Globe Newswire|
|7/22/2022||DocGo to Exhibit Innovative Vehicles at 2022 Subway Series Mets vs. Yankees Game in NYC | Business Wire||Business Wire|
|7/22/2022||ORYZON Reports Results and Corporate Update for Half-Year Ending June 30, 2022||Yahoo News|
|7/22/2022||ORYZON Reports Results and Corporate Update for Half-Year||Globe Newswire|
|7/22/2022||DocGo to Exhibit Innovative Vehicles at 2022 Subway Series Mets vs. Yankees Game in NYC||Business Wire|
|7/21/2022||OptimizeRx Sets Second Quarter Fiscal 2022 Conference Call for Tuesday, August 9 at 4:30 p.m. ET||Globe Newswire|
|7/21/2022||Relmada Therapeutics Appoints Biopharmaceutical Marketing and Commercial Planning Veteran John Hixon as Head of Commercial||PR Newswire|
|7/21/2022||Motus GI to Release Second Quarter Results and Provide a||Globe Newswire|
|7/21/2022||Motus GI Holdings (MOTS) Motus GI to Release Second Quarter Results and Provide a Business Update on August 11||researchpool.com|
|7/19/2022||HTG Molecular Diagnostics Hosting a KOL Event Addressing Drug Candidate Attrition||Globe Newswire|
|7/19/2022||Clene Receives Positive EMA Opinion on Orphan Drug||Globe Newswire|
|7/19/2022||SCYNEXIS Presents Positive Data from Phase 3 CANDLE Nested Sub-Study Investigating Ibrexafungerp in Women with Recurrent Yeast Infections Who Failed Fluconazole During the ISSVD XXVI World Congress and International Vulvovaginal Disease Update||Globe Newswire|
|7/19/2022||Capricor Therapeutics Announces First Patient Dosed in Pivotal Phase 3 Study of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy||Globe Newswire|
|7/19/2022||Allena Pharmaceuticals Announces Completion of Enrollment of Cohorts A and B of ALLN-346 Phase 2a Study 202 in Patients with Gout and Stages 2 and 3 Chronic Kidney Disease||Globe Newswire|
|7/18/2022||HTG Molecular Diagnostics Announces Amendment to Senior||Globe Newswire|
|7/14/2022||Amryt Receives Orphan Drug Designation from the FDA for Mycapssa¬Æ (oral octreotide) for the Treatment of Carcinoid Syndrome||Globe Newswire|
|7/14/2022||Biora Therapeutics Shares Preclinical Data on Oral Delivery of Biologics at Controlled Release Society 2022||Globe Newswire|
|7/14/2022||TFF Pharmaceuticals Expands R&D Operations with New Austin||Globe Newswire|
|7/13/2022||Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)||Globe Newswire|
|7/13/2022||scPharmaceuticals Inc. to Participate in the Maxim Group LLC Late-Stage Advancements in Heart Failure Therapeutics and Management Panel Discussion||Globe Newswire|